Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC-1180 in Healthy Subjects
NCT07300189Phase 1Recruiting
- Sponsor
- OrsoBio
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TLC-1180 (2 arms), sponsored by OrsoBio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 421, Area Under the Curve at Day 421 and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
TLC-1180
Beyond the preview
Go deeper on NCT07300189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300189.